Treatments for Sexual Wellness
Reignite desire with PT-141 — a physician-prescribed therapy that works on the brain pathways behind wanting, for women and men.
Get to the root of it
Getting started is risk-free. Upload your labs and we'll track them — 40+ biomarkers, reviewed by a licensed provider to personalize your plan.
Get started
Desire starts in the brain, not just the body
Low libido is often a brain-signalling problem, not a blood-flow one. PT-141 works on the desire circuitry itself — a different pathway from erection-focused drugs.
The desire pathway
PT-141 (bremelanotide) activates the brain's melanocortin system — the circuitry behind wanting, not just the physical response.
For women and men
One of the few desire therapies studied across genders. In its branded injectable form it is FDA-approved for premenopausal women; other uses are off-label.
On-demand, not daily
Taken as a needle-free nasal spray about 45 minutes before intimacy — used as needed, with blood pressure monitored by your physician.
Feel like yourself again.
Physician-led. Properly monitored.
PT-141 acts on the melanocortin pathways behind sexual desire. We prescribe and monitor it under physician supervision — including blood-pressure screening.
Desire in women
In two phase-3 trials, bremelanotide improved sexual desire and reduced distress versus placebo in premenopausal women (Obstetrics & Gynecology, 2019)
Studied in men
In men, subcutaneous bremelanotide produced erectile responses in an early controlled study — an off-label, investigational use (Int J Impot Res, 2004)
How it works
Take the 2–min health quiz
US licensed doctor reviews & approves
Treatment is shipped in discreet packaging
Track & optimize with your doctor
Every batch tested
U.S.-licensed
Regulated sources